NASDAQ: LXEOLexeo Therapeutics Inc Stock
$3.94-0.15 (-3.67%)
Updated Jun 13, 2025
LXEO Price
$3.94
Fair Value Price
$0.79
Market Cap
$130.80M
52 Week Low
$1.45
52 Week High
$19.50
P/E
-1.19x
P/B
1.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$109.31M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.43
Operating Cash Flow
-$88M
Beta
1.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LXEO Overview
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LXEO's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LXEO
Ranked#437 of 464
Ranked#437 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important LXEO news, forecast changes, insider trades & much more!
LXEO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LXEO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LXEO ($3.94) is overvalued by 399.17% relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LXEO ($3.94) is not significantly undervalued (399.17%) relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LXEO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LXEO due diligence checks available for Premium users.
Valuation
LXEO fair value
Fair Value of LXEO stock based on Discounted Cash Flow (DCF)
Price
$3.94
Fair Value
$0.79
Overvalued by
399.17%
LXEO ($3.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LXEO ($3.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LXEO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LXEO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.19x
Industry
-108.97x
Market
31.36x
LXEO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.48x
Industry
4.66x
LXEO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LXEO's financial health
Profit margin
Revenue
$0.0
Net Income
-$32.7M
Profit Margin
0%
LXEO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$125.7M
Liabilities
$37.6M
Debt to equity
0.43
LXEO's short-term assets ($105.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LXEO's short-term assets ($105.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LXEO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.7M
Investing
$15.6M
Financing
$11.0k
LXEO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LXEO vs Biotech Stocks
Lexeo Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.